Celltrion Healthcare, which handles Celltrion's overseas business, announced on Feb. 18, 2020 that Remsima SC was successfully released in Germany.
According to Celltrion Healthcare Vice Chairman Kim Hyeong-gi, Remsima SC is the first prescription for autoimmune diseases that the company is selling through a direct sales system. Kim urged that sales of Remsima SC will be a barometer to evaluate the sales system of Celltrion Healthcare.
Remsima SC is a treatment for autoimmune disease, which was approved for use last November in Europe. Kim stated that Remsima SC is quite convenient for patients since it changes the injection from an intravenous (IV) version to a subcutaneous one.
Celltrion earlier announced that Remsima SC will be sold directly in Europe without any foreign partners. By setting the price of the biosimilar higher than the first-line treatment and lower than the second-line treatment, Celtrion intends to expand sales of Remsima SC in European markets, including Germany, the U.K. and the Netherlands.
According to IQVIA data, Germany’s tumor necrosis factor-alpha (TNFα) market is estimated to be almost $1.9 billion. Since Germany is one of the most significant European healthcare markets, and Celltrion Healthcare released Remsima SC in Germany first.
Professor Rieke Alten, head of the Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik in Berlin stated that Remsima SC is significantly useful in terms of safety and efficacy similarly to Remsima IV.
Alten added that Remsima SC has a very positive reputation among the German medical community since physicians could prescribe infliximab as a single drug in a changed drug form.
One of Celltrion Healthcare’s officials also mentioned that he was surprised to see the first prescription of Remsima SC just a week after German doctors requested information about clinical data on the drug.
Celltrion Healthcare Vice Chairman Kim added that the company plans to recruit more than 300 employees with professional marketing capabilities.